Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Progress in the development of a therapeutic vaccine for breast cancer.

Literature DB >> 24367164

Progress in the development of a therapeutic vaccine for breast cancer.

Andrew L Coveler¹, Nicole E Bates¹, Mary L Disis¹.

Abstract

Various human malignancies are immunogenic and recent cancer vaccine trials have demonstrated potential survival benefit. Breast cancer is immunogenic and there are several tumor associated antigens for which breast cancer vaccines have been developed. Breast cancer vaccines are designed to stimulate the immune response at various steps in the native antigen processing pathway for immunosurveillance. Human epidermal growth factor receptor 2 (HER-2/neu), mucin 1 (MUC-1), and human telomerase reverse transcriptase (hTERT) are some of the most studied antigens actively being targeted for vaccination in breast cancer patients. These vaccines are designed to elicit cytotoxic and/or helper T cell responses. Over the last several years, there has been reported progress in human clinical trials for these antigens. Cancer vaccines have repeatedly been shown to be safe with production of minimal toxicity. Recent clinical advances in the development of cancer vaccines demonstrate the potential clinical benefit that cancer vaccines hold.

Entities: Disease Gene Species

Keywords: HER-2/neu; MUC-1; breast; cancer; hTERT; vaccine

Year: 2010 PMID： 24367164 PMCID： PMC3846461 DOI： 10.2147/bctt.s6956

Source DB: PubMed Journal: Breast Cancer (Dove Med Press) ISSN： 1179-1314

57 in total

1. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506

2. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.

Authors: S von Mensdorff-Pouilly; A A Verstraeten; P Kenemans; F G Snijdewint; A Kok; G J Van Kamp; M A Paul; P J Van Diest; S Meijer; J Hilgers
Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544

3. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors: Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal: J Clin Oncol Date: 2002-02-01 Impact factor: 44.544

4. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Authors: R H Collins; O Shpilberg; W R Drobyski; D L Porter; S Giralt; R Champlin; S A Goodman; S N Wolff; W Hu; C Verfaillie; A List; W Dalton; N Ognoskie; A Chetrit; J H Antin; J Nemunaitis
Journal: J Clin Oncol Date: 1997-02 Impact factor: 44.544

5. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245

6. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Authors: Linda C Benavides; Jeremy D Gates; Mark G Carmichael; Ritesh Patil; Ritesh Patel; Jarrod P Holmes; Matthew T Hueman; Elizabeth A Mittendorf; Dianna Craig; Alexander Stojadinovic; Sathibalan Ponniah; George E Peoples
Journal: Clin Cancer Res Date: 2009-04-07 Impact factor: 12.531

7. Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers.

Authors: Lupe G Salazar; Andrew L Coveler; Ron E Swensen; Theodore A Gooley; Vivian Goodell; Kathy Schiffman; Mary L Disis
Journal: Clin Immunol Date: 2007-10-29 Impact factor: 3.969

8. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

Authors: S A Rosenberg; J C Yang; D E White; S M Steinberg
Journal: Ann Surg Date: 1998-09 Impact factor: 12.969

9. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors: Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal: N Engl J Med Date: 2003-01-16 Impact factor: 91.245

10. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Authors: George E Peoples; Jarrod P Holmes; Matthew T Hueman; Elizabeth A Mittendorf; Asna Amin; Steven Khoo; Zia A Dehqanzada; Jennifer M Gurney; Michael M Woll; Gayle B Ryan; Catherine E Storrer; Dianna Craig; Constantin G Ioannides; Sathibalan Ponniah
Journal: Clin Cancer Res Date: 2008-02-01 Impact factor: 12.531

6 in total

Progress in the development of a therapeutic vaccine for breast cancer.

1. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

2. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.

3. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

4. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

5. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

6. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

7. Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers.

8. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

9. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

10. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

1. Immunotherapy for Breast Cancer: What Are We Missing?

2. Autophagy is decreased in triple-negative breast carcinoma involving likely the MUC1-EGFR-NEU1 signalling pathway.

Review 3. Recent advances in the development of breast cancer vaccines.

Review 4. Breast Cancer Vaccines: New Insights.

Review 5. Prophylactic Cancer Vaccines Engineered to Elicit Specific Adaptive Immune Response.

6. Antitumor activity of SA12, a novel peptide, on SKBr-3 breast cancer cells via the mitochondrial apoptosis pathway.